IL211267A - Oxadiazole derivatives and drugs and their use in the treatment of diabetes - Google Patents

Oxadiazole derivatives and drugs and their use in the treatment of diabetes

Info

Publication number
IL211267A
IL211267A IL211267A IL21126711A IL211267A IL 211267 A IL211267 A IL 211267A IL 211267 A IL211267 A IL 211267A IL 21126711 A IL21126711 A IL 21126711A IL 211267 A IL211267 A IL 211267A
Authority
IL
Israel
Prior art keywords
medicaments
diabetes
treatment
oxadiazole derivatives
oxadiazole
Prior art date
Application number
IL211267A
Other languages
English (en)
Hebrew (he)
Other versions
IL211267A0 (en
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of IL211267A0 publication Critical patent/IL211267A0/en
Publication of IL211267A publication Critical patent/IL211267A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
IL211267A 2008-08-18 2011-02-17 Oxadiazole derivatives and drugs and their use in the treatment of diabetes IL211267A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008038220A DE102008038220A1 (de) 2008-08-18 2008-08-18 Oxadiazolderivate
PCT/EP2009/004992 WO2010020305A1 (de) 2008-08-18 2009-07-09 Oxadiazolderivate für die behandlung von diabetes

Publications (2)

Publication Number Publication Date
IL211267A0 IL211267A0 (en) 2011-04-28
IL211267A true IL211267A (en) 2015-07-30

Family

ID=41010866

Family Applications (1)

Application Number Title Priority Date Filing Date
IL211267A IL211267A (en) 2008-08-18 2011-02-17 Oxadiazole derivatives and drugs and their use in the treatment of diabetes

Country Status (9)

Country Link
US (1) US8377975B2 (enExample)
EP (1) EP2313380B1 (enExample)
JP (1) JP5571665B2 (enExample)
AU (1) AU2009284453B2 (enExample)
CA (1) CA2734397C (enExample)
DE (1) DE102008038220A1 (enExample)
ES (1) ES2444129T3 (enExample)
IL (1) IL211267A (enExample)
WO (1) WO2010020305A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10252984B2 (en) 2011-10-27 2019-04-09 Mayo Foundation For Medical Education And Research Inhibiting G protein coupled receptor 6 kinase polypeptides
DE102013226711A1 (de) * 2013-12-19 2015-06-25 Beiersdorf Ag Verwendung von Alkylamidothiazolen in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
WO2015164411A2 (en) 2014-04-21 2015-10-29 Mayo Foundation For Medical Education And Research Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides
WO2019040404A1 (en) * 2017-08-21 2019-02-28 Microbiotix, Inc. METABOLIC-STABLE METABOLIC-N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS
US11447482B1 (en) 2019-02-14 2022-09-20 KUDA Therapeutics, Inc. Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE35261C (de) FIRMA CARL UHL & CO. in Braunschweig Neuerung an Stimmschrauben
DD35261A1 (de) * 1962-08-31 1965-02-15 Verfahren zur Herstellung von 5-substituierten 2-Amino-1,3,4-oxdiazolen
US3790588A (en) * 1969-10-24 1974-02-05 Gulf Research Development Co Method of manufacturing dialkylamino-1,3,4-oxadiazoles and 1,3,4-thiadiazoles
NZ227841A (en) 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
NZ231534A (en) * 1988-11-29 1992-02-25 Warner Lambert Co 3,5-di-t-butyl-4-hydroxyphenyl-triazoles, oxadiazoles and thiadiazoles; anti-inflammatory compositions
US5256680A (en) * 1988-11-29 1993-10-26 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
US5155122A (en) * 1988-11-29 1992-10-13 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
DE19917990A1 (de) 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
DE10042137A1 (de) 2000-08-28 2002-03-14 Florian Lang sgk2 und sgk3 als diagnostische und therapeutische Targets
EP1377549A1 (en) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
US20030108403A1 (en) 2001-12-14 2003-06-12 Scoyoc James E. Van Fluid flow bolt system
WO2003051847A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003227741A1 (en) 2002-05-17 2003-12-02 Pharmacia Italia S.P.A. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003293376A1 (en) 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US20050019366A1 (en) 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
WO2005064375A1 (en) 2003-12-24 2005-07-14 Pirelli & C. S.P.A. Low loss microring resonator device
WO2005105788A1 (en) 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
EP1751133B1 (en) * 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
JP5275628B2 (ja) * 2004-08-25 2013-08-28 ターゲジェン インコーポレーティッド 複素環式化合物および使用方法
AU2005295441B2 (en) 2004-10-18 2009-04-23 Amgen, Inc. Thiadiazole compounds and methods of use
AU2005315430B2 (en) 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
WO2006064375A2 (en) 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
JP5144532B2 (ja) 2005-11-30 2013-02-13 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔ阻害剤及び用法
AU2006331912B2 (en) 2005-12-21 2012-08-30 Janssen Pharmaceutica, N.V. Triazolopyridazines as tyrosine kinase modulators
CA2651979A1 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
DE102006048728A1 (de) * 2006-10-16 2008-04-17 Merck Patent Gmbh 3-Amino-imidazo{1,2-a]pyridinderivate
EA016527B1 (ru) 2006-10-23 2012-05-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Триазолопиридазиновые модуляторы протеинкиназ
EP1939187A1 (en) 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate

Also Published As

Publication number Publication date
IL211267A0 (en) 2011-04-28
CA2734397A1 (en) 2010-02-25
EP2313380A1 (de) 2011-04-27
DE102008038220A1 (de) 2010-02-25
CA2734397C (en) 2016-09-20
ES2444129T3 (es) 2014-02-24
EP2313380B1 (de) 2013-12-11
AU2009284453B2 (en) 2014-02-20
AU2009284453A1 (en) 2010-02-25
WO2010020305A1 (de) 2010-02-25
US20110139654A1 (en) 2011-06-16
US8377975B2 (en) 2013-02-19
JP5571665B2 (ja) 2014-08-13
JP2012500232A (ja) 2012-01-05

Similar Documents

Publication Publication Date Title
IL210856A0 (en) Combination therapy for the treatment of diabetes and related conditions
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
IL219945A (en) 1-GLP history with dual transduction and use of it to prepare a drug for the treatment of diabetes
ZA200805716B (en) Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
IL210589A (en) C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB
IL259475A (en) Combined therapy for the treatment of diabetes
IL213168A0 (en) 1,2,4-oxadiazole derivatives and their therapeutic use
IL219529A (en) Annotated 4-aminocyclohexane history, medications containing them and the use of history to prepare pain medication
IL212064A (en) Use of pirpenidone in the preparation of a drug for the treatment of patients with atypical liver function
ZA201202560B (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
GB0817207D0 (en) therapeutic apsac compounds and their use
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
IL205608A (en) History of s-triazole-1-ram-benzamide and their use in the preparation of pain medication
IL207520A0 (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
IL214260A0 (en) Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof
IL212672A (en) Cycloandesdepsipeptide compounds and their use in drug production
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL200032A0 (en) Medicament for the treatment of endometriosis
IL211267A (en) Oxadiazole derivatives and drugs and their use in the treatment of diabetes
ZA201007061B (en) Pyridopyrazinones derivatives insulin secretion stimulators,methods for obtaining them and use thereof for the treatment of diabetes
EP2276505A4 (en) USE OF MATERIAL FOR MANUFACTURING A MEDICAMENT FOR TREATING A BANAL COLD
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
ZA201008505B (en) Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
ZA200905300B (en) Medicament for the treatment of endometriosis
GB0712626D0 (en) Medicament for the treatment of endometriosis

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed